# SC-101

Source: https://onco.cc/drugs/sc-101/  
OnCo record `sc-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SC-101 is an experimental peptide-drug conjugate from ConjuStar Biologics, in phase 2 trials for nectin-4-expressing advanced solid tumours, NECTIN4-amplified triple-negative breast cancer and NECTIN4-amplified HR-positive breast cancer.

## Summary

SC-101 is a peptide-drug conjugate from ConjuStar Biologics. A peptide-drug conjugate that targets Nectin-4; the payload is not stated in the sources read. Its furthest stage is phase 2, for nectin-4-expressing advanced solid tumours, NECTIN4-amplified triple-negative breast cancer and NECTIN4-amplified HR-positive breast cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 in Nectin-4-expressing solid tumours recruiting (NCT06220838; dose-escalation results at ESMO 2025). Phase 2a in NECTIN4-amplified tumours recruiting (NCT07080619). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: SC-101
- Modality: Peptide-drug conjugate
- Mechanism: A peptide-drug conjugate that targets Nectin-4; the payload is not stated in the sources read.

## Sources

- ConjuStar Biologics: conjustar.com: https://www.conjustar.com/
- ConjuStar Biologics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07080619
- ConjuStar Biologics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06220838
- ClinicalTrials.gov: trials of SC-101: https://clinicaltrials.gov/search?intr=SC-101

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/)
- companies: [ConjuStar Biologics](https://onco.cc/companies/conjustar-biologics/)
- trials: [SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers](https://onco.cc/trials/nct07080619/), [Study SC-101 in Subjects With Advanced Malignancies](https://onco.cc/trials/nct06220838/)

---
JSON: https://onco.cc/api/v1/entities/sc-101.json